A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α‐reductase inhibitors GI198745 and finasteride

@article{Gisleskog1998AMF,
  title={A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α‐reductase inhibitors GI198745 and finasteride},
  author={P. O. Gisleskog and D. Hermann and M. Hammarlund-Udenaes and M. Karlsson},
  journal={Clinical Pharmacology & Therapeutics},
  year={1998},
  volume={64}
}
  • P. O. Gisleskog, D. Hermann, +1 author M. Karlsson
  • Published 1998
  • Chemistry, Medicine
  • Clinical Pharmacology & Therapeutics
  • To develop a pharmacokinetic‐pharmacodynamic model that characterizes the conversion of testosterone to dihydrotestosterone (DHT) by 5α‐reductase types 1 and 2 and the irreversible inhibition of 5α‐reductase by finasteride, a 5α‐reductase type 2 inhibitor and by GI198745 (dutasteride), a potent and specific dual 5α‐reductase inhibitor. 
    54 Citations
    A new look at the 5alpha-reductase inhibitor finasteride.
    • 117
    Estimating the contribution of the prostate to blood dihydrotestosterone.
    • 30
    • PDF
    The effect of 5 alpha-reductase inhibitors on erectile function.
    • 32
    Finasteride in the treatment of alopecia
    • 69
    • Highly Influenced

    References

    SHOWING 1-10 OF 32 REFERENCES
    Finasteride: a slow-binding 5 alpha-reductase inhibitor.
    • 69
    Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR.
    • 135
    • PDF
    Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.
    • 140
    Clinical Pharmacokinetics and Pharmacodynamics of Finasteride
    • 89